Strong Investor Demand as Meds Debuts on Nasdaq First North
Meds' IPO garners strong investor interest ahead of its successful market debut.
- • Meds' IPO significantly oversubscribed before debut.
- • Shares priced at 53 kronor, valuing company over one billion kronor.
- • Average annual growth rate of 39% and revenue exceeded half a billion kronor in H1 2025.
- • Funds will enhance logistics automation and improve customer experience.
Key details
Meds, a leading Swedish online pharmacy, has received overwhelming interest in its initial public offering (IPO), leading to a significant oversubscription just ahead of its stock market debut on September 23, 2025. The company plans to debut on Nasdaq First North with shares priced at 53 kronor, which values it at over one billion kronor. This reflects strong investor confidence in Meds’ promising growth trajectory, which has seen the company achieve an average annual growth rate of 39% over the past four years. Revenue surpassed half a billion kronor in the first half of 2025, outpacing much of the overall market growth.
CEO Björn Thorgren emphasized the strategic focus on logistics automation, with funds from the IPO primarily directed toward enhancing operational efficiencies. Thorgren described the pharmacy market’s stability, remarking, "The important thing is to always have the right goods in stock, deliver on time, and make the shopping experience easy. If you succeed with that, customers will return and recommend us further."